Seeley, Martha

Seeley, Martha was paid $777K by Medicaid between Jan 2018 and Jun 2019, across 9 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.

33Billing provider infoSEELEY, MARTHA
GLASGOW, KY 42141

33aNPI1417920224assigned 02/10/2006

33bProvider typeFamily Medicine Physician

28Total paid$777K

24GClaims16,207

24DCodes billed9

24AFirst – last monthJan 2018 – Jun 2019

Compared with peers

Next to other Family Medicine Physician providers in Kentucky

Rank by total paid#78 of 352

Median peer was paid$90K

This provider vs. median8.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	9,767	$460K
2019	6,440	$318K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	35%	7,151	3,023	$269K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	29%	2,496	1,270	$225K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	24%	1,623	780	$190K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.1%	873	469	$39K
80305		4.9%	3,535	1,709	$38K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	1.2%	187	152	$10K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	221	107	$6K
36415	Collection of venous blood by venipuncture	<1%	104	95	$330.25
81025		<1%	17	16	$114.23

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.